Cellectar Reports Iopofosine I 131 Data in BTKi-Refractory Waldenström Macroglobulinemia
FLORHAM PARK, N.J. — September 29, 2026 Cellectar Biosciences announced that a subset analysis from the Phase 2 CLOVER-WaM...
hematologic cancer
Advertisement
Johnson & Johnson TECVAYLI Gains Positive CHMP Opinion
Raritan, New Jersey, U.S., September 18, 2026 Johnson & Johnson has announced that the European Medicines Agency’s Committee for...
Ipsen Completes Kartos Acquisition to Expand Oncology Pipeline
Paris, France | August 21, 2026 Ipsen announced the completion of its acquisition of Kartos Therapeutics, strengthening its late-stage...
Curis Reaffirms Initial Patient Dosing Timeline for TakeAim CLL Trial
LEXINGTON, Mass., June 26, 2026 Curis, Inc. announced continued progress in its Phase 2 TakeAim CLL clinical trial, confirming...
Karyopharm Highlights Phase 3 SENTRY Trial Progress in Myelofibrosis
NEWTON, Mass., June 1, 2026 Karyopharm Therapeutics has announced that it will host an investor conference call featuring leading...
Advertisements
PeproMene Bio CAR-T Therapy Shows Durable Lymphoma Responses
IRVINE, California, May 29, 2026 PeproMene Bio, Inc. has announced that updated clinical data from its ongoing Phase 1...
Taiho Oncology Wins FDA Approval for INQOVI Combo
PRINCETON, N.J. and TOKYO, May 13, 2026 Taiho Oncology and Taiho Pharmaceutical announced that the U.S. Food and Drug...
BeOne Medicines Wins FDA Approval for BEQALZI in Mantle Cell Lymphoma
SAN CARLOS, Calif., May 13, 2026 BeOne Medicines announced that the U.S. Food and Drug Administration (FDA) has granted...
PureTech Reports Positive LYT-200 Phase 1b Trial Data
BOSTON, USA, April 22, 2026 PureTech Health plc has announced positive topline results from its Phase 1b clinical trial...
Karyopharm SENTRY Trial Advances Myelofibrosis Treatment
Newton, Massachusetts, USA, April 21, 2026 In a major development in hematologic oncology, Karyopharm Therapeutics Inc. has announced that...
Advertisement
